Affiliation:
1. Bayer HealthCare AG, Pharma Research EU, Wuppertal, Germany
Abstract
ABSTRACT
Novel N-3-alkylated 6-anilinouracils have been identified as potent and selective inhibitors of bacterial DNA polymerase IIIC, the enzyme essential for the replication of chromosomal DNA in gram-positive bacteria. A nonradioactive assay measuring the enzymatic activity of the DNA polymerase IIIC in gram-positive bacteria has been assembled. The 6-anilinouracils described inhibited the polymerase IIIC enzyme at concentrations in the nanomolar range in this assay and displayed good in vitro activity (according to their MICs) against staphylococci, streptococci, and enterococci. The MICs of the most potent derivatives were about 4 μg/ml for this panel of bacteria. The 50% effective dose of the best compound (6-[(3-ethyl-4-methylphenyl)amino]-3-{[1-(isoxazol-5-ylcarbonyl)piperidin-4-yl]methyl}uracil) was 10 mg/kg of body weight after intravenous application in a staphylococcal sepsis model in mice, from which in vivo pharmacokinetic data were also acquired.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference31 articles.
1. Ali, A., S. D. Aster, D. W. Graham, G. F. Patel, G. E. Taylor, R. L. Tolman, R. E. Painter, L. L. Silver, K. Young, K. Ellsworth, W. Geissler, and G. S. Harris. 2001. Design and synthesis of novel antimicrobial agents with inhibitory activity against DNA polymerase III. Bioorg. Med. Chem. Lett.11:2185-2188.
2. Ali, A., G. E. Taylor, K. Ellsworth, G. Harris, R. Painter, L. L. Silver, and K. Young. 2003. Novel pyrazolo[3,4-d]pyrimidine-based inhibitors of Staphylococcus aureus DNA polymerase III: design, synthesis, and biological evaluation. J. Med. Chem.46:1824-1830.
3. Ali A. G. E. Taylor and D. W. Graham. April 2001. Gram-positive selective antibacterial compounds compositions containing such compounds and methods of treatment. Patent WO 01/29010.
4. Barnes, M. H., R. A. Hammond, C. C. Kennedy, S. L. Mack, and N. C. Brown. 1992. Localization of the exonuclease and polymerase domains of Bacillus subtilis DNA polymerase III. Gene111:43-49.
5. Bhamidipati, R. K., P. V. Dravid, R. Mullangi, and N. R. Srinivas. 2004. Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones. Xenobiotica34:571-579.
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献